title: Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
abstract: BACKGROUND
  In type 2 diabetes mellitus, fasting blood glucose values are increased due to increased glycogenolysis and gluconeogenesis. As miglitol (BAY m-1099), an absorbable alpha-glucosidase inhibitor, can inhibit glycogenolysis, we investigated whether 200 mg miglitol ingested at bedtime could decrease fasting blood glucose values.
  
  
  METHODS
  Twelve type 2 diabetic patients participated in a double-blind, randomised, placebo-controlled, cross-over study. The study duration was 6 weeks: 2 weeks run-in, 2 test periods of 1 week with 2 weeks of wash-out in between. During run-in and wash-out periods placebo tablets were used. Fasting blood glucose (FBG), insulin (FIRI), C-peptide (FCP), glucagon (FG), pyruvate and alanine were measured at the start of the study, at the end of the run-in and wash-out periods, and at the 6th and 7th day of each test period.
  
  
  RESULTS
  Both during miglitol and placebo no effects on FBG (12.2 +/- 2.5 vs. 12.2 +/- 2.5 mmol/l), FIRI (80 +/- 34 vs. 82 +/- 35 pmol/l), FCP (1110 +/- 303 vs. 1043 +/- 304 pmol/l), FG (20 +/- 13 vs. 20 +/- 10 pmol/l), pyruvate (101 +/- 28 vs. 112 +/- 30 mumol/l) or alanine (440 +/- 87 vs. 465 +/- 133 mumol/l) were observed.
  
  
  CONCLUSIONS
  Miglitol 200 mg taken at bedtime for 1 week has no influence on hepatic glucose production.
authors.affiliation: Department of Internal Medicine, University Hospital, Maastricht, Netherlands.
authors.forename: J P
authors.initials: JP
authors.lastname: Sels
authors.forename: P J
authors.initials: PJ
authors.lastname: Kingma
authors.forename: B H
authors.initials: BH
authors.lastname: Wolffenbuttel
authors.forename: P P
authors.initials: PP
authors.lastname: Menheere
authors.forename: J H
authors.initials: JH
authors.lastname: Branolte
authors.forename: A C
authors.initials: AC
authors.lastname: Nieuwenhuijzen Kruseman
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D005944:Glucosamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D050112:Imino Pyranoses; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D050112:Imino Pyranoses; C045621:miglitol; D017485:1-Deoxynojirimycin; D005944:Glucosamine